Follicular Lymphoma

Drug Name: Lunsumio Active Ingredient: mosunetuzumab-axgb Indications: To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma Approval Date: 12/22/2022 Company: Genentech, Inc Learn more:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf